EDISON EQUITY RESEARCH - CAPSTONE THERAPEUTICS

EDISON EQUITY RESEARCH - CAPSTONE THERAPEUTICS:

FIRST HUMAN LIPID BIOMARKER TRENDS

Early data in healthy volunteers have demonstrated trends in favour of AEM-28 on a number of lipid biomarkers, even at low doses. These are the first-in-man data, which hint at potential future efficacy. AEM-28 continues to be investigated in a Phase Ib/IIa trial, with data anticipated by YE14/Q115. These could pave the way for future development in an orphan cardiovascular indication, although additional funds will likely be needed if data are positive.

 Capstone Therapeutics’ lead candidate AEM-28 is currently in a Phase I/II clinical trial for orphan disease homozygous familial hypercholesterolemia. AEM-28 also has potential in broader CV indications. Capstone owns 60% of AEM-28 through a JV with LipimetiX Development.

 To view our full report, please click here: 

http://www.edisoninvestmentresearch.com/research/report/capstone-therapeutics1

Click here

 to view all of Edison Investment Research's published reports.